StoneWise, a medical technology company that accelerates novel drug discovery with artificial intelligence, announced that it has completed its series B and B+ financing to raise a total of US$100 million. The series B financing was led by Legend Capital, while the series B+ funding was co-led by Greater Bay Area Community Development Fund and Lightspeed China. New investors include CDH VGC Fund and Eastern Bell Capital. Existing shareholders HillHouse Ventures, SIG, Long Hill Capital, and Linear Capital made additional investments. The proceeds will be used to recruit and retain world-leading talents and upgrade the AI-enabled drug discovery platform so as to advance innovation and improve R&D efficiency. “We will use the proceeds from these two rounds of financing to strengthenour talent team, accelerate technology i...

On November 12, 2020, Eli Lilly and Company and Seed Therapeutics, Inc. (a subsidiary of BeyondSpring, hereinafter referred to as " BeyondSpring Seed"), partner of StoneWise has reached a US $790 million cooperative development agreement for jointly using its new protein degradation technology platform to develop new drugs, and StoneWise AIDD platform promoted the agreement as an underlying technical support party with computational biology, virtual screening and rational design. Therefore, from the deal, it well demonstrates that StoneWise and BeyondSpring Seed are leading and innovating the technology in the field of protein degradation drug research and development. StoneWise and BeyondSpring Seed reached a cooperation in early 2020, making use of artificial intelligence + computational chemistry platform to provide compound screening a...

In a campaign to screen drugs for the COVID-19, the disease caused by SARS-CoV-2, treatment, StoneWise, a company specialized in applying artificial intelligence to innovative drug design solutions for innovative drug R&D enterprises and institutions, has conducted research and been sharing the electronic structure data of more than 1400 nucleoside inhibitors against various RNA polymerases from patents up to February 5, 2020. Using its proprietary AI-driven drug design platform, StoneWise has ranked dozens of nucleosides from these molecules as potential inhibitors against SARS-CoV-2 RNA polymerase. StoneWise hereby makes all the related data freely available to the scientific community for further research and development. The download links are enclosed at the end of this article. Furthermore, ...